Treatment of the alcoholic organic brain syndrome: double-blind, placebo-controlled clinical, psychometric and electroencephalographic mapping studies with modafinil.
In a double-blind study 40 abstinent hospitalized male patients with an alcoholic organic brain syndrome (OBS; ICD 9: 291.2) were treated for 6 weeks with either placebo or 200 mg modafinil b.i.d. Modafinil (CRL 40476) is a vigilance-promoting, putative central alpha 1-adrenergic agonist with a pharmacological profile quite different from that of amphetamine. Clinical investigations demonstrated that the spontaneous remission of the alcoholic OBS was augmented and accelerated by modafinil, which was found significant as compared with placebo by confirmatory statistics in the target variable, the Clinical Global Impression scale. The drug was well tolerated. Psychometric tests revealed significant improvement of the noopsyche after modafinil as compared with placebo, while the thymopsyche and psychophysiological measurements were not affected. Electroencephalographic mapping showed significant differences between the central effects of modafinil and placebo indicating an improvement of vigilance under modafinil. Typical vigilance-promoting properties were seen after acute drug administration, were less evident before the morning dose after chronic treatment but re-occurred after super-imposed daily drug administration. Thus, our clinical, psychometric and neurophysiological investigations in alcoholic OBS patients demonstrated a therapeutic effect of modafinil in the early phase of abstinence.
Saletu
B
B
Department of Psychiatry, School of Medicine, University of Vienna, Austria.
Saletu
M
M
Grünberger
J
J
Frey
R
R
Anderer
P
P
Mader
R
R
D000328:Adult; D000437:Alcoholism / Q000150:complications* / Q000503:physiopathology / Q000523:psychology; D000704:Analysis of Variance; D001559:Benzhydryl Compounds / Q000627:therapeutic use*; D001921:Brain / Q000503:physiopathology*; D001931:Brain Mapping; D000697:Central Nervous System Stimulants / Q000627:therapeutic use*; D004311:Double-Blind Method; D004569:Electroencephalography; D006801:Humans; D008297:Male; D008875:Middle Aged; D000077408:Modafinil; D011594:Psychometrics; D019966:Substance-Related Disorders / Q000188:drug therapy* / Q000503:physiopathology / Q000523:psychology
D001559:Benzhydryl Compounds; D000697:Central Nervous System Stimulants; D000077408:Modafinil